Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Sep 6, 2024
Distillery Therapeutics
CAR T cells targeting FGFR4 and B7-H3 for pediatric rhabdomyosarcoma
BioCentury | Mar 25, 2022
Discovery & Translation
AACR22 tackles the CAR T solid tumor challenge
Dual-targeting CARs, new targets and bispecific adaptors among the top innovations
BioCentury | Jul 14, 2020
Deals
Roche deal clears path for Blueprint’s financial independence
Blueprint receives $775M up front, diagnostic capabilities via licensing deal for RET inhibitor pralsetinib
BioCentury | Jun 4, 2020
Finance
Everest to fund late-stage trials with $310M mountain of fresh cash
Largest venture round yet for an Asian therapeutics play could tee up an IPO at a valuation in the billions
BioCentury | Jul 17, 2019
Company News
Abbisko builds combination strategy with China rights to X4's mavorixafor
BioCentury | Oct 25, 2018
Targets & Mechanisms
Blueprint for selectivity
Why Blueprint thinks its selective ALK2 inhibition is the best bet for treating FOP
BioCentury | Aug 31, 2018
Financial News
Principia seeks IPO ahead of Phase III trials for Btk program
Items per page:
1 - 10 of 31